

Demystifying complexities of opioid dependence related to chronic pain

Dr Yasir Abbasi

Liverpool
UK



Disclosures

- Receipt of honoraria or consultation fees: Indivior, Martindale, Mundipharma, Bite Medical

Learning objective

After this presentation, participants should be able to:

- **Discuss the challenges of identifying and managing patients with opioid analgesic dependence (OAD) and describe how these challenges can be overcome**


Interactive question

- On a scale of A–E, how confident are you in identifying individuals with OAD?




Interactive question


- On a scale of A–E, how confident are you in managing pain in individuals on opioid agonist therapy?



Two main groups impacted by chronic pain and opioid dependence in Europe



Chronic pain patients who develop OAD



But first, what is chronic pain?

**A type of pain that has
persisted beyond normal tissue
healing time –
usually ~3 months**

**Prevalence:
~19% of adults in Europe
~13% of adults in the UK**


Weak opioids:
Codeine, dihydrocodeine

**Opioid analgesics are
often used to treat
chronic pain**


Strong opioids:
Morphine,
buprenorphine, fentanyl,
methadone,
oxycodone, tapentadol,
tramadol

The scale of the problem

OA use for pain management has dramatically increased worldwide over the last decade



2001-2003



2011-2013

Incidence of OAD



Access to
opioid analgesia
is **increasing in
Western Europe**,
mirroring the trend
seen in Australia and
North America

4.7%

Incidence of
OAD in those
prescribed
opioids for
chronic care

Important to remember

Majority of chronic
pain patients using
OA do not develop
opioid dependence

Why treat OAD?

OAD has social, psychological and physical consequences for the patient

Physical

- Vary with opioid intoxication, overdose or withdrawal
- Long-term effects
 - Endocrine changes
 - Immunological effects
 - Sleep disorders

Social

- Loss of employment
- Marital and family breakdown
- Loss of friendships
- Loss of interest in regular activities
- Financial problems

Psychological

- Mood instability
- Agitation
- Anxiety
- Depression

Risk factors for OAD

OAD may result from a combination of factors, including:



**Personal or family
history of
dependence**



**Genetic
predisposition**



**Personal
psychological
profile**



**Drug
exposure**




**Alterations in
brain reward
mechanisms**

History of dependence is the
strongest predictor

Studies have indicated rates of
mental health issues in OAD
individuals as high as 72.9%

Pathway to dependence



Barriers and challenges of addressing OAD

Engagement often suboptimal

Patients often:

- do not seek help
- lack awareness of the problem
- fear being stigmatised



OAD diagnosis often not made

HCPs may lack awareness and knowledge of the issue



Pathway of referral to a specialist may be unclear




Lack of integrated approach


Success may be limited by lack of integration between opioid dependence and pain management



OAD prevention: safer prescribing of OAs initially



Limit dose escalation
if inadequate pain relief



Regularly review
analgesia use with patient



Provide support for stopping
if opioid trial not working



Avoid treatments that are
unlikely to be beneficial



Avoid prescribing an opioid
as 'default'
Consider non-pharmacological
interventions



Provide training and
education among HCPs

Factors that may indicate possible addiction

Adverse consequence:

- Intoxicated/somnolent/sedated
- Decreased activity
- Irritable/anxious/labile
- Increased sleep disturbances
- Increased pain complaints
- Increased relationship dysfunction

Impaired control/compulsive use:

- Repeated reports of lost or stolen Rx or Mx
- Frequent early renewal requests
- Urgent calls or unscheduled visits
- Misuse of other drugs and/or alcohol
- Withdrawal noted at clinic visits
- Observers report overuse or sporadic use

Preoccupation with use due to craving:

- Frequent missed appointments unless opioid renewal expected
- Does not try non-opioid treatments
- Cannot 'tolerate' most medications
- Requests specific medication/controlled drugs

Screening tools to assess risk of misuse

A single-question screening test

'How many times in the past year have you used an illegal drug or used a prescription medication for non-medical reasons?' (positive answer >0)^[1]

ORT Opioid Risk Tool

Assesses risk of aberrant behaviours — low-, moderate- or high-risk user. 5 items. Approx. 1 min to complete^[2]

<http://www.agencymeddirectors.wa.gov/files/opioidrisktool.pdf>

SOAPP Screener & Opioid Assessment for Patients with Pain

Assesses suitability of long-term opioid therapy from chronic pain patients. Different versions: 8, 14 or 24 items^{[3][4]}

http://nationalpaincentre.mcmaster.ca/documents/soapp_r_sample_watermark.pdf

SISAP The Screening Instrument for Substance Abuse Potential

Identifies individuals with a possible substance abuse history and at risk of misusing opioids. 5 items. Approx. <1 min to complete^[5]

<https://www.integration.samhsa.gov/clinical-practice/screening-tools#drugs>


DAST-10 Drug Abuse Screening Test

Assesses degree of problems related to drug abuse. 10 items. Yes/no self-report instrument. Should take <8 mins to complete^[6]


https://www.bu.edu/bniart/files/2012/04/DAST-10_Institute.pdf

Survey of OAD awareness among mental health professionals

Respondents thought patients presenting with the following problems are misusing or have developed OAD



OAD treatment options



Key points

- ✓ Choice of OAT medication should be tailored to each individual
- ✓ Intensive monitoring is required
- ✓ Adjustments of dose may be necessary
- ✓ Consider role of psychosocial support
- ✓ Certain individuals with complex comorbidities may benefit from an in-patient setting
- ✓ Cessation of OAT should be guided by clinical response and not stopped prematurely

Long-term opioid users who develop chronic pain



Long-term heroin users with chronic pain



**Increasing due to an ageing
population**

**At risk of undertreatment due to
misconceptions**

OAT alone
provides
enough
analgesia

Use of OA
may result in
relapse



Management recommendations

- ✓ Have **realistic** goals
- ✓ For patients on OAT experiencing pain, consider **dividing daily dose** into every 8 or 12 hours
- ✓ Consider **non-opioid analgesia** where they have demonstrated efficacy for the pain condition reported
- ✓ Consider **non-pharmacological** options

May only be able to achieve reductions in pain intensity and not complete relief

For example, physical rehabilitation, exercise and psychological treatments

Case example

- 38-year-old white British male
- Works for emergency services
- Had an **accident** 8 years ago
 - Slipped and fractured wrist
- **Continued** to have '**pain**' for 2 years
- **Prescribed analgesia** by GP
- When prescription stopped, began **buying analgesia OTC**
 - Took 68 tablets of 8/500 mg codeine/paracetamol both in the morning and at night for 3 years
- Referred by GP to our service after they failed a codeine-only taper
- We stabilised the patient on **low-dose methadone** (20 mg/day) with **psychosocial interventions**
- Within 6 months, the patient was referred for **in-patient detox** as he struggled reducing it at home
- Patient then completed a successful detox
- He is **now abstinent** and **back at work**

Case example

Previous medical history

Nil

Past psychological history

Drank alcohol excessively 10 years ago but had since reduced and stopped – still abstinent. No previous psychological diagnosis but had underlying low mood

Family history

Father had 'alcohol issues'. Mother and brother diagnosed with GAD

Personal history

He had been working for the emergency services for 14 years. Had a partner and two children (14-year-old boy and 8-year-old girl)



Integrated and multidisciplinary approach is key

